PROMOT Network receives funding from EJP-RD to develop an adaptable precision medicine approach for four NMDs

We are excited to announce a successful grant application from NMD4C steering committee members Dr Cynthia Gagnon (lead investigator), Dr Hanns Lochmüller, and Dr Homira Osman for the PROMOT network: Performing a Rare Disease-Oriented Master Observational Trial to decipher complexity and optimize trial readiness. Funded by the European Joint Programme for Rare Diseases (EJP-RD), with Canadian funding contributed by the Canadian Institutes for Health Research (CIHR), the PROMOT network is a joint international collaboration involving sites across Canada, Sweden, Spain, France, Switzerland and Ireland, with a total funding amount of approximately $2 million over a 3-year period.

The PROMOT network project aims to develop a precision medicine approach that is adaptable to several rare diseases, including NMDs. Presently, a precision medicine approach requires an individual natural history study for each rare disease, with high financial and research costs associated with each study. The network’s approach will consolidate several rare NMDs into a single multi-faceted natural history study, allowing a greater number of NMDs to be studied concurrently to reduce cost-associated barriers while producing cross-validated outcome measures and improving the time to clinical trial readiness.

Combining an innovative natural history study design, adapted Master Observational Trial (MOT), and artificial intelligence (AI), the PROMOT network will respond to several unmet needs found in most rare NMDs, including prognosis and clinical trial readiness with the goals of identifying potential biomarkers amenable to treatments and providing protocols for use in clinical trials.

The PROMOT network will first develop the MOT for Oculopharyngeal Muscular Dystrophy (OPMD) alongside three neuromuscular disorders (NMDs) with shared commonalities: myofibrillar myopathies, congenital myopathies, congenital myasthenia. The MOT will then be tested in neuromuscular clinics located in Canada and internationally to document the feasibility of using this approach in rare diseases under different global health systems. To foster knowledge mobilization, the PROMOT network will create a learning and mobilization platform (LEAP FORWARD) with MDC to host clinical, physiological and behavioral outcomes data to allow insight into disease impact, which will include an interface accessible by patients and healthcare professionals.

From a neuromuscular patient and family perspective, time is one of the most important factors in disease progression; this transdisciplinary and intersectoral research project will accelerate the time to receiving a prognosis and clinical trial readiness in four NMDs. By breaking research silos within and across rare diseases, the PROMOT network’s innovative approach has the potential to reduce these delay times for patients across many more rare diseases in the future.

EJPRD

Read next...

Journal of neuromuscular diseases

Journal of Neuromuscular Diseases Celebrates 10-Year Anniversary with Commemorative Editorial

The January 2024 edition of the Journal of Neuromuscular Diseases (JND) marked the journal’s 10-year anniversary!

Canadian Neuromuscular Community of Practice

NMD4C and MDC Announce Plans for Neuromuscular Community of Practice

We are thrilled to announce a new neuromuscular Community of Practice (CoP) initiative for neuromuscular healthcare providers! Our CoP will address the need for a centralized hub for neuromuscular HCPs, fostering collaboration, knowledge exchange, and skill enhancement to elevate NMD research and care across Canada. 

NMD4C investigators' research named to Quebec Science Magazine's top 10 discoveries of 2023

NMD4C Investigators’ Research Named to Quebec Science Magazine’s Top 10 Discoveries of 2023

The 31st edition of the Quebec Science magazine’s Top 10 Discoveries of the Year has recognized a publication from NMD4C investigators in their 2023 list of top scientific discoveries from Québec-based researchers. 

Defeat Duchenne grant $17 million over 29-years to fund promising Duchenne research.

Defeat Duchenne Canada Announce 2023-2024 Research Grants

Defeat Duchenne Canada, announce that it will grant $880,320 toward five promising research projects this year.

NMD4C welcomes two new staff members - Marine Christin, PhD and Maria Masnata, PhD

NMD4C Welcomes Two New Staff Members

The NMD4C recently welcomed two new members to the network coordination team! Marine Christin, PhD joins us as the new Pre-Clinical Science Coordinator, and Maria Masnata, PhD joins as the Clinical Trials & Community Practice Manager. 

Congratulations to the 2024 neuromuscular clinical and post-doctoral fellowship recipients. Photos of the fellows with information about their research insitutions.

2024 Recipients of NMD4C and MDC Neuromuscular Fellowship Funding Competition

The Neuromuscular Disease Network for Canada (NMD4C) together with Muscular Dystrophy Canada (MDC) are thrilled to announce the recipients of the National Clinical and Post-doctoral Fellowships funding competition.